Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti‐PD‐1 efficacy

The efficacy of anti‐PD‐1 therapy is not as expected in hepatocellular carcinoma (HCC). YAP1 was overexpressed and activated in HCC. The mechanism of YAP1 in HCC immune escape is unclear. Anti‐PD‐1 treatment increased YAP1 expression in liver tumor cells, and exhausted CD4+ and CD8+ T cells in the b...

Full description

Saved in:
Bibliographic Details
Published inPhytotherapy research Vol. 37; no. 5; pp. 1740 - 1753
Main Authors Peng, Qing, Li, Shenghao, Shi, Xinli, Guo, Yinglin, Hao, Liyuan, Zhang, Zhiqin, Ji, Jingmin, Zhao, Yanmeng, Li, Caige, Xue, Yu, Liu, Yiwei
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.05.2023
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The efficacy of anti‐PD‐1 therapy is not as expected in hepatocellular carcinoma (HCC). YAP1 was overexpressed and activated in HCC. The mechanism of YAP1 in HCC immune escape is unclear. Anti‐PD‐1 treatment increased YAP1 expression in liver tumor cells, and exhausted CD4+ and CD8+ T cells in the blood and spleen of liver tumor mice. YAP1 knockdown suppressed PD‐L1 expression, which was involved in JAK1/STAT1, 3 pathways. Moreover, Yap1 knockout elevated CD4+ and CD8+ T cells in liver tumor niche. Consistently, verteporfin, YAP1 inhibitor, decreased TGF‐β and IFN‐γ in liver tumor niche and exhausted CD8+ T cell in the spleen. DHA suppressed YAP1 expression and break immune evasion in liver tumor niche, characterized by decreased PD‐L1 in liver tumor cells and increased CD8+ T cell infiltration. Furthermore, DHA combined with anti‐PD‐1 treatment promoted CD4+ T cell infiltration in the spleen and CD8+ T cell in tumor tissues of mice. In summary, YAP1 knockdown in liver tumor cells suppressed PD‐L1 expression and recruited cytotoxic T lymphocytes (CTLs), leading to break immune evasion in tumor niche. Mechanistically, YAP1 knockdown suppressed PD‐L1 expression, which was involved in JAK1/STAT1, 3 pathways. Finally, DHA inhibited YAP1 expression, which not only inhibited liver tumor proliferation but also break the immunosuppressive niche in liver tumor tissues and improve the effect of anti‐PD‐1 therapy.
AbstractList The efficacy of anti‐PD‐1 therapy is not as expected in hepatocellular carcinoma (HCC). YAP1 was overexpressed and activated in HCC. The mechanism of YAP1 in HCC immune escape is unclear. Anti‐PD‐1 treatment increased YAP1 expression in liver tumor cells, and exhausted CD4+ and CD8+ T cells in the blood and spleen of liver tumor mice. YAP1 knockdown suppressed PD‐L1 expression, which was involved in JAK1/STAT1, 3 pathways. Moreover, Yap1 knockout elevated CD4+ and CD8+ T cells in liver tumor niche. Consistently, verteporfin, YAP1 inhibitor, decreased TGF‐β and IFN‐γ in liver tumor niche and exhausted CD8+ T cell in the spleen. DHA suppressed YAP1 expression and break immune evasion in liver tumor niche, characterized by decreased PD‐L1 in liver tumor cells and increased CD8+ T cell infiltration. Furthermore, DHA combined with anti‐PD‐1 treatment promoted CD4+ T cell infiltration in the spleen and CD8+ T cell in tumor tissues of mice. In summary, YAP1 knockdown in liver tumor cells suppressed PD‐L1 expression and recruited cytotoxic T lymphocytes (CTLs), leading to break immune evasion in tumor niche. Mechanistically, YAP1 knockdown suppressed PD‐L1 expression, which was involved in JAK1/STAT1, 3 pathways. Finally, DHA inhibited YAP1 expression, which not only inhibited liver tumor proliferation but also break the immunosuppressive niche in liver tumor tissues and improve the effect of anti‐PD‐1 therapy.
The efficacy of anti-PD-1 therapy is not as expected in hepatocellular carcinoma (HCC). YAP1 was overexpressed and activated in HCC. The mechanism of YAP1 in HCC immune escape is unclear. Anti-PD-1 treatment increased YAP1 expression in liver tumor cells, and exhausted CD4 and CD8 T cells in the blood and spleen of liver tumor mice. YAP1 knockdown suppressed PD-L1 expression, which was involved in JAK1/STAT1, 3 pathways. Moreover, Yap1 knockout elevated CD4 and CD8 T cells in liver tumor niche. Consistently, verteporfin, YAP1 inhibitor, decreased TGF-β and IFN-γ in liver tumor niche and exhausted CD8 T cell in the spleen. DHA suppressed YAP1 expression and break immune evasion in liver tumor niche, characterized by decreased PD-L1 in liver tumor cells and increased CD8 T cell infiltration. Furthermore, DHA combined with anti-PD-1 treatment promoted CD4 T cell infiltration in the spleen and CD8 T cell in tumor tissues of mice. In summary, YAP1 knockdown in liver tumor cells suppressed PD-L1 expression and recruited cytotoxic T lymphocytes (CTLs), leading to break immune evasion in tumor niche. Mechanistically, YAP1 knockdown suppressed PD-L1 expression, which was involved in JAK1/STAT1, 3 pathways. Finally, DHA inhibited YAP1 expression, which not only inhibited liver tumor proliferation but also break the immunosuppressive niche in liver tumor tissues and improve the effect of anti-PD-1 therapy.
Abstract The efficacy of anti‐PD‐1 therapy is not as expected in hepatocellular carcinoma (HCC). YAP1 was overexpressed and activated in HCC. The mechanism of YAP1 in HCC immune escape is unclear. Anti‐PD‐1 treatment increased YAP1 expression in liver tumor cells, and exhausted CD4 + and CD8 + T cells in the blood and spleen of liver tumor mice. YAP1 knockdown suppressed PD‐L1 expression, which was involved in JAK1/STAT1, 3 pathways. Moreover, Yap1 knockout elevated CD4 + and CD8 + T cells in liver tumor niche. Consistently, verteporfin, YAP1 inhibitor, decreased TGF‐β and IFN‐γ in liver tumor niche and exhausted CD8 + T cell in the spleen. DHA suppressed YAP1 expression and break immune evasion in liver tumor niche, characterized by decreased PD‐L1 in liver tumor cells and increased CD8 + T cell infiltration. Furthermore, DHA combined with anti‐PD‐1 treatment promoted CD4 + T cell infiltration in the spleen and CD8 + T cell in tumor tissues of mice. In summary, YAP1 knockdown in liver tumor cells suppressed PD‐L1 expression and recruited cytotoxic T lymphocytes (CTLs), leading to break immune evasion in tumor niche. Mechanistically, YAP1 knockdown suppressed PD‐L1 expression, which was involved in JAK1/STAT1, 3 pathways. Finally, DHA inhibited YAP1 expression, which not only inhibited liver tumor proliferation but also break the immunosuppressive niche in liver tumor tissues and improve the effect of anti‐PD‐1 therapy.
Author Guo, Yinglin
Zhao, Yanmeng
Liu, Yiwei
Peng, Qing
Li, Shenghao
Xue, Yu
Ji, Jingmin
Shi, Xinli
Hao, Liyuan
Zhang, Zhiqin
Li, Caige
Author_xml – sequence: 1
  givenname: Qing
  orcidid: 0000-0002-2238-8400
  surname: Peng
  fullname: Peng, Qing
  organization: Hebei University of Chinese Medicine
– sequence: 2
  givenname: Shenghao
  surname: Li
  fullname: Li, Shenghao
  organization: Hebei University of Chinese Medicine
– sequence: 3
  givenname: Xinli
  surname: Shi
  fullname: Shi, Xinli
  email: sxlsunshine@sina.com
  organization: Hebei University of Chinese Medicine
– sequence: 4
  givenname: Yinglin
  surname: Guo
  fullname: Guo, Yinglin
  organization: Hebei University of Chinese Medicine
– sequence: 5
  givenname: Liyuan
  orcidid: 0000-0001-9429-5134
  surname: Hao
  fullname: Hao, Liyuan
  organization: Hebei University of Chinese Medicine
– sequence: 6
  givenname: Zhiqin
  surname: Zhang
  fullname: Zhang, Zhiqin
  organization: Hebei University of Chinese Medicine
– sequence: 7
  givenname: Jingmin
  surname: Ji
  fullname: Ji, Jingmin
  organization: Hebei University of Chinese Medicine
– sequence: 8
  givenname: Yanmeng
  surname: Zhao
  fullname: Zhao, Yanmeng
  organization: Hebei University of Chinese Medicine
– sequence: 9
  givenname: Caige
  surname: Li
  fullname: Li, Caige
  organization: Hebei University of Chinese Medicine
– sequence: 10
  givenname: Yu
  surname: Xue
  fullname: Xue, Yu
  organization: Hebei University of Chinese Medicine
– sequence: 11
  givenname: Yiwei
  surname: Liu
  fullname: Liu, Yiwei
  organization: Hebei University of Chinese Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36576358$$D View this record in MEDLINE/PubMed
BookMark eNp1kc9qFTEUh4O02Nsq-AQScONm2iQzSSbL0voPCr2UCroKmeRcb-qdZExmqrPrpnuf0Scx9dYKBRfnnM3Hxznnt492QgyA0AtKDikh7GgY06EUij9BC0qUqiiX9Q5aEMVp1dD20x7az_mKEKIYaZ6ivVpwKWreLtDtqV_PLkWTRuh99sEH3KX4FfC4LjX1MWHf91OIeRqGBDn7a8C9tylCuPYphh7CiLsZ-7D2nR99-II_Hy8phh9bPAY8RgxhbYIFbMLof938XJ6WVpjVyltj52dod2U2GZ7fzwP08e2by5P31dn5uw8nx2eVrRvFK8PA1EwSqZwg3PJaKiYcgHIdY040jjjFbAsGRNsB4Q1YsEY4qVojObf1AXq99Q4pfpsgj7rcbGGzMQHilDWTXJUviVYU9NUj9CpOKZTtNGspbWopeftPWP6Rc4KVHpLvTZo1JfouGl2i0XfRFPTlvXDqenAP4N8sClBtge9-A_N_RXp5efFH-BtVa56a
CitedBy_id crossref_primary_10_3389_fimmu_2023_1323581
crossref_primary_10_3389_fimmu_2024_1377722
crossref_primary_10_1007_s00210_024_03123_6
crossref_primary_10_1016_j_acthis_2024_152171
crossref_primary_10_1016_j_bcp_2024_116294
crossref_primary_10_1186_s13020_023_00785_x
crossref_primary_10_3390_ijms242417322
Cites_doi 10.1016/j.molcel.2007.12.022
10.3389/fonc.2020.595466
10.1016/j.celrep.2017.04.031
10.1002/ptr.6332
10.1080/2162402x.2018.1438106
10.1016/j.bbrc.2017.07.007
10.1097/cji.0000000000000187
10.1007/s00109-018-1717-7
10.1016/j.csbj.2019.03.006
10.3389/fimmu.2017.01597
10.1073/pnas.0810958105
10.1002/hep.28710
10.1016/j.jdermsci.2020.08.001
10.1080/14728222.2018.1471137
10.1186/s40425-019-0814-7
10.1016/j.cell.2015.10.044
10.3892/ol.2021.12914
10.3389/fgene.2019.00422
10.1172/jci126022
10.16288/j.yczz.17-064
10.1158/2159-8290.cd-15-0224
10.1371/journal.pbio.3000591
10.1186/s13046-019-1403-9
10.1177/0022034517712435
10.1101/gad.294348.116
10.1016/j.ccr.2009.12.048
10.1053/j.gastro.2016.05.006
10.1007/s11010-020-03861-0
10.1172/jci88486
10.1016/j.cell.2012.11.026
10.1158/2326-6066.Cir-17-0320
10.1158/1078-0432.ccr-20-3365
10.1007/s11418-022-01641-2
10.1007/s00262-017-2086-8
10.1038/s41590-018-0044-z
10.1159/000464380
10.7554/eLife.67312
10.18632/oncotarget.17520
10.1158/1535-7163.Mct-20-0024
ContentType Journal Article
Copyright 2022 John Wiley & Sons Ltd.
2023 John Wiley & Sons, Ltd.
Copyright_xml – notice: 2022 John Wiley & Sons Ltd.
– notice: 2023 John Wiley & Sons, Ltd.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QO
7QP
7QR
7TK
7TM
8FD
FR3
K9.
P64
RC3
7X8
DOI 10.1002/ptr.7695
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Biotechnology Research Abstracts
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Genetics Abstracts
Biotechnology Research Abstracts
Technology Research Database
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList Genetics Abstracts
MEDLINE

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
Botany
EISSN 1099-1573
EndPage 1753
ExternalDocumentID 10_1002_ptr_7695
36576358
PTR7695
Genre article
Journal Article
Commentary
Editorial
GrantInformation_xml – fundername: National Natural Science Foundation of China
  funderid: 81873112
– fundername: National Natural Science Foundation of China
  grantid: 81873112
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
123
1L6
1OB
1OC
1ZS
31~
33P
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHBH
AAHHS
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAYOK
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
EBD
EBS
ECGQY
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
GWYGA
H.X
HF~
HGLYW
HHY
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M6Q
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
UB1
V2E
V8K
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WOHZO
WQJ
WRC
WUP
WVDHM
WWP
WXI
WXSBR
XG1
XV2
YCJ
ZZTAW
~IA
~KM
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QO
7QP
7QR
7TK
7TM
8FD
FR3
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c3495-a2ea327079d605c537926dee9db22d64d0d92c8eae68be054ececa6d798a755c3
IEDL.DBID DR2
ISSN 0951-418X
IngestDate Thu Aug 15 23:35:32 EDT 2024
Thu Oct 10 22:03:26 EDT 2024
Fri Aug 23 03:36:36 EDT 2024
Sat Sep 28 08:14:32 EDT 2024
Sat Aug 24 00:54:32 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Dihydroartemisinin
YAP1
PD-L1
immune microenvironment
hepatocellular carcinoma
Language English
License 2022 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3495-a2ea327079d605c537926dee9db22d64d0d92c8eae68be054ececa6d798a755c3
Notes Qing Peng and Shenghao Li contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-2238-8400
0000-0001-9429-5134
PMID 36576358
PQID 2811437758
PQPubID 1036338
PageCount 14
ParticipantIDs proquest_miscellaneous_2759000686
proquest_journals_2811437758
crossref_primary_10_1002_ptr_7695
pubmed_primary_36576358
wiley_primary_10_1002_ptr_7695_PTR7695
PublicationCentury 2000
PublicationDate May 2023
2023-May
2023-05-00
20230501
PublicationDateYYYYMMDD 2023-05-01
PublicationDate_xml – month: 05
  year: 2023
  text: May 2023
PublicationDecade 2020
PublicationPlace Chichester, UK
PublicationPlace_xml – name: Chichester, UK
– name: England
– name: Bognor Regis
PublicationSubtitle PTR
PublicationTitle Phytotherapy research
PublicationTitleAlternate Phytother Res
PublicationYear 2023
Publisher John Wiley & Sons, Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Ltd
– name: Wiley Subscription Services, Inc
References 2017; 40
2019; 7
2015; 163
2021; 27
2017; 41
2017; 8
2021; 22
2019; 97
2019; 33
2010; 17
2019; 10
2019; 17
2019; 38
2017; 491
2008; 105
2020; 99
2019; 129
2020; 10
2018; 67
2018; 22
2020; 19
2020; 18
2018; 7
2018; 6
2018; 19
2012; 151
2017; 31
2016; 6
2017; 96
2021; 10
2022
2017; 39
2008; 29
2016; 64
2017; 19
2020; 475
2017; 127
2016; 151
e_1_2_9_30_1
e_1_2_9_31_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_10_1
e_1_2_9_35_1
e_1_2_9_13_1
e_1_2_9_32_1
e_1_2_9_12_1
e_1_2_9_33_1
e_1_2_9_15_1
e_1_2_9_38_1
e_1_2_9_14_1
e_1_2_9_39_1
e_1_2_9_17_1
e_1_2_9_36_1
e_1_2_9_16_1
e_1_2_9_37_1
e_1_2_9_19_1
e_1_2_9_18_1
e_1_2_9_20_1
e_1_2_9_40_1
e_1_2_9_22_1
e_1_2_9_21_1
e_1_2_9_24_1
e_1_2_9_23_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_4_1
e_1_2_9_3_1
e_1_2_9_2_1
e_1_2_9_9_1
e_1_2_9_26_1
e_1_2_9_25_1
e_1_2_9_28_1
e_1_2_9_27_1
e_1_2_9_29_1
References_xml – volume: 38
  start-page: 397
  issue: 1
  year: 2019
  article-title: IFN‐gamma‐induced PD‐L1 expression in melanoma depends on p53 expression
  publication-title: Journal of Experimental & Clinical Cancer Research
– volume: 10
  year: 2020
  article-title: Eliminating radiation resistance of non‐small cell lung cancer by Dihydroartemisinin through abrogating immunity escaping and promoting radiation sensitivity by inhibiting PD‐L1 expression
  publication-title: Frontiers in Oncology
– volume: 10
  year: 2021
  article-title: YAP and TAZ are transcriptional co‐activators of AP‐1 proteins and STAT3 during breast cellular transformation
  publication-title: eLife
– year: 2022
  article-title: Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma
  publication-title: Journal of Natural Medicines
– volume: 8
  start-page: 45981
  issue: 28
  year: 2017
  end-page: 45993
  article-title: Dihydroartemisinin induces autophagy‐dependent death in human tongue squamous cell carcinoma cells through DNA double‐strand break‐mediated oxidative stress
  publication-title: Oncotarget
– volume: 33
  start-page: 1413
  issue: 5
  year: 2019
  end-page: 1425
  article-title: Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells
  publication-title: Phytotherapy Research
– volume: 6
  start-page: 255
  issue: 3
  year: 2018
  end-page: 266
  article-title: YAP‐induced PD‐L1 expression drives immune evasion in BRAFi‐resistant melanoma
  publication-title: Cancer Immunology Research
– volume: 19
  start-page: 2175
  issue: 10
  year: 2020
  end-page: 2185
  article-title: Concurrent targeting of potential cancer stem cells regulating pathways sensitizes lung adenocarcinoma to standard chemotherapy
  publication-title: Molecular Cancer Therapeutics
– volume: 17
  start-page: 661
  year: 2019
  end-page: 674
  article-title: Application of PD‐1 blockade in cancer immunotherapy
  publication-title: Computational and Structural Biotechnology Journal
– volume: 19
  start-page: 222
  issue: 3
  year: 2018
  end-page: 232
  article-title: The immunology of hepatocellular carcinoma
  publication-title: Nature Immunology
– volume: 129
  start-page: 3324
  issue: 8
  year: 2019
  end-page: 3338
  article-title: IL‐6/JAK1 pathway drives PD‐L1 Y112 phosphorylation to promote cancer immune evasion
  publication-title: The Journal of Clinical Investigation
– volume: 39
  start-page: 607
  issue: 7
  year: 2017
  end-page: 616
  article-title: Hippo signaling pathway in liver tissue homeostasis
  publication-title: Yi Chuan
– volume: 17
  start-page: 286
  issue: 3
  year: 2010
  end-page: 297
  article-title: Hepatocyte IKKbeta/NF‐kappaB inhibits tumor promotion and progression by preventing oxidative stress‐driven STAT3 activation
  publication-title: Cancer Cell
– volume: 67
  start-page: 271
  issue: 2
  year: 2018
  end-page: 283
  article-title: Cross‐talk between TNF‐α and IFN‐γ signaling in induction of B7‐H1 expression in hepatocellular carcinoma cells
  publication-title: Cancer Immunology, Immunotherapy
– volume: 31
  start-page: 247
  issue: 3
  year: 2017
  end-page: 259
  article-title: Single tumor‐initiating cells evade immune clearance by recruiting type II macrophages
  publication-title: Genes & Development
– volume: 22
  start-page: 547
  issue: 6
  year: 2018
  end-page: 557
  article-title: Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD‐L1 in human breast cancer cells
  publication-title: Expert Opinion on Therapeutic Targets
– volume: 8
  year: 2017
  article-title: PD‐1/PD‐L1 blockade: Have we found the key to unleash the antitumor immune response?
  publication-title: Frontiers in Immunology
– volume: 40
  start-page: 323
  issue: 9
  year: 2017
  end-page: 333
  article-title: Relationship between PD‐L1 expression and CD8+ T‐cell immune responses in hepatocellular carcinoma
  publication-title: Journal of Immunotherapy
– volume: 64
  start-page: 2038
  issue: 6
  year: 2016
  end-page: 2046
  article-title: Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship with clinical and pathological features
  publication-title: Hepatology
– volume: 151
  start-page: 526
  issue: 3
  year: 2016
  end-page: 539
  article-title: YAP1 and TAZ control pancreatic cancer initiation in mice by direct up‐regulation of JAK‐STAT3 signaling
  publication-title: Gastroenterology
– volume: 475
  start-page: 79
  issue: 1–2
  year: 2020
  end-page: 91
  article-title: Cisplatin promotes the expression level of PD‐L1 in the microenvironment of hepatocellular carcinoma through YAP1
  publication-title: Molecular and Cellular Biochemistry
– volume: 22
  start-page: 653
  issue: 3
  year: 2021
  article-title: Anti‐malarial drug dihydroartemisinin downregulates the expression levels of CDK1 and CCNB1 in liver cancer
  publication-title: Oncology Letters
– volume: 491
  start-page: 493
  issue: 2
  year: 2017
  end-page: 499
  article-title: Hippo effector YAP directly regulates the expression of PD‐L1 transcripts in EGFR‐TKI‐resistant lung adenocarcinoma
  publication-title: Biochemical and Biophysical Research Communications
– volume: 7
  issue: 6
  year: 2018
  article-title: Melanoma response to anti‐PD‐L1 immunotherapy requires JAK1 signaling, but not JAK2
  publication-title: Oncoimmunology
– volume: 27
  start-page: 3432
  issue: 12
  year: 2021
  end-page: 3442
  article-title: Mutations in the IFNγ‐JAK‐STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment
  publication-title: Clinical Cancer Research
– volume: 105
  start-page: 20852
  issue: 52
  year: 2008
  end-page: 20857
  article-title: Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD‐L1, B7‐H1)
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 127
  start-page: 137
  issue: 1
  year: 2017
  end-page: 152
  article-title: Hippo signaling interactions with Wnt/β‐catenin and notch signaling repress liver tumorigenesis
  publication-title: The Journal of Clinical Investigation
– volume: 97
  start-page: 77
  issue: 1
  year: 2019
  end-page: 88
  article-title: Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma
  publication-title: Journal of Molecular Medicine (Berlin, Germany)
– volume: 6
  start-page: 80
  issue: 1
  year: 2016
  end-page: 95
  article-title: Targeting YAP‐dependent MDSC infiltration impairs tumor progression
  publication-title: Cancer Discovery
– volume: 18
  issue: 1
  year: 2020
  article-title: Yap suppresses T‐cell function and infiltration in the tumor microenvironment
  publication-title: PLoS Biology
– volume: 29
  start-page: 350
  issue: 3
  year: 2008
  end-page: 361
  article-title: Yap1 phosphorylation by c‐Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage
  publication-title: Molecular Cell
– volume: 96
  start-page: 1027
  issue: 9
  year: 2017
  end-page: 1034
  article-title: STAT3 induces immunosuppression by upregulating PD‐1/PD‐L1 in HNSCC
  publication-title: Journal of Dental Research
– volume: 19
  start-page: 1189
  issue: 6
  year: 2017
  end-page: 1201
  article-title: Interferon receptor signaling pathways regulating PD‐L1 and PD‐L2 expression
  publication-title: Cell Reports
– volume: 163
  start-page: 811
  issue: 4
  year: 2015
  end-page: 828
  article-title: Hippo pathway in organ size control, tissue homeostasis, and cancer
  publication-title: Cell
– volume: 10
  year: 2019
  article-title: EZH2 regulates protein stability via recruiting USP7 to mediate neuronal gene expression in cancer cells
  publication-title: Frontiers in Genetics
– volume: 151
  start-page: 1457
  issue: 7
  year: 2012
  end-page: 1473
  article-title: β‐Catenin‐driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis
  publication-title: Cell
– volume: 99
  start-page: 193
  issue: 3
  year: 2020
  end-page: 202
  article-title: Dihydroartemisinin inhibits melanoma by regulating CTL/Treg anti‐tumor immunity and STAT3‐mediated apoptosis via IL‐10 dependent manner
  publication-title: Journal of Dermatological Science
– volume: 41
  start-page: 1189
  issue: 3
  year: 2017
  end-page: 1198
  article-title: YAP‐1 promotes Tregs differentiation in hepatocellular carcinoma by enhancing TGFBR2 transcription
  publication-title: Cellular Physiology and Biochemistry
– volume: 7
  start-page: 19
  issue: 1
  year: 2019
  end-page: 814
  article-title: PD1(hi) CD8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma
  publication-title: Journal for Immunotherapy of Cancer
– ident: e_1_2_9_17_1
  doi: 10.1016/j.molcel.2007.12.022
– ident: e_1_2_9_40_1
  doi: 10.3389/fonc.2020.595466
– ident: e_1_2_9_6_1
  doi: 10.1016/j.celrep.2017.04.031
– ident: e_1_2_9_31_1
  doi: 10.1002/ptr.6332
– ident: e_1_2_9_21_1
  doi: 10.1080/2162402x.2018.1438106
– ident: e_1_2_9_15_1
  doi: 10.1016/j.bbrc.2017.07.007
– ident: e_1_2_9_12_1
  doi: 10.1097/cji.0000000000000187
– ident: e_1_2_9_22_1
  doi: 10.1007/s00109-018-1717-7
– ident: e_1_2_9_36_1
  doi: 10.1016/j.csbj.2019.03.006
– ident: e_1_2_9_37_1
  doi: 10.3389/fimmu.2017.01597
– ident: e_1_2_9_24_1
  doi: 10.1073/pnas.0810958105
– ident: e_1_2_9_3_1
  doi: 10.1002/hep.28710
– ident: e_1_2_9_39_1
  doi: 10.1016/j.jdermsci.2020.08.001
– ident: e_1_2_9_29_1
  doi: 10.1080/14728222.2018.1471137
– ident: e_1_2_9_23_1
  doi: 10.1186/s40425-019-0814-7
– ident: e_1_2_9_38_1
  doi: 10.1016/j.cell.2015.10.044
– ident: e_1_2_9_9_1
  doi: 10.3892/ol.2021.12914
– ident: e_1_2_9_16_1
  doi: 10.3389/fgene.2019.00422
– ident: e_1_2_9_4_1
  doi: 10.1172/jci126022
– ident: e_1_2_9_20_1
  doi: 10.16288/j.yczz.17-064
– ident: e_1_2_9_35_1
  doi: 10.1158/2159-8290.cd-15-0224
– ident: e_1_2_9_33_1
  doi: 10.1371/journal.pbio.3000591
– ident: e_1_2_9_34_1
  doi: 10.1186/s13046-019-1403-9
– ident: e_1_2_9_2_1
  doi: 10.1177/0022034517712435
– ident: e_1_2_9_8_1
  doi: 10.1101/gad.294348.116
– ident: e_1_2_9_10_1
  doi: 10.1016/j.ccr.2009.12.048
– ident: e_1_2_9_7_1
  doi: 10.1053/j.gastro.2016.05.006
– ident: e_1_2_9_19_1
  doi: 10.1007/s11010-020-03861-0
– ident: e_1_2_9_14_1
  doi: 10.1172/jci88486
– ident: e_1_2_9_28_1
  doi: 10.1016/j.cell.2012.11.026
– ident: e_1_2_9_13_1
  doi: 10.1158/2326-6066.Cir-17-0320
– ident: e_1_2_9_25_1
  doi: 10.1158/1078-0432.ccr-20-3365
– ident: e_1_2_9_26_1
  doi: 10.1007/s11418-022-01641-2
– ident: e_1_2_9_18_1
  doi: 10.1007/s00262-017-2086-8
– ident: e_1_2_9_27_1
  doi: 10.1038/s41590-018-0044-z
– ident: e_1_2_9_5_1
  doi: 10.1159/000464380
– ident: e_1_2_9_11_1
  doi: 10.7554/eLife.67312
– ident: e_1_2_9_30_1
  doi: 10.18632/oncotarget.17520
– ident: e_1_2_9_32_1
  doi: 10.1158/1535-7163.Mct-20-0024
SSID ssj0009204
Score 2.4858086
Snippet The efficacy of anti‐PD‐1 therapy is not as expected in hepatocellular carcinoma (HCC). YAP1 was overexpressed and activated in HCC. The mechanism of YAP1 in...
The efficacy of anti-PD-1 therapy is not as expected in hepatocellular carcinoma (HCC). YAP1 was overexpressed and activated in HCC. The mechanism of YAP1 in...
Abstract The efficacy of anti‐PD‐1 therapy is not as expected in hepatocellular carcinoma (HCC). YAP1 was overexpressed and activated in HCC. The mechanism of...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 1740
SubjectTerms Adaptor Proteins, Signal Transducing - metabolism
Animal tissues
Animals
B7-H1 Antigen
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - metabolism
CD4 antigen
CD8 antigen
CD8-Positive T-Lymphocytes
Cytotoxicity
Dihydroartemisinin
Effectiveness
Hepatocellular carcinoma
Hepatocytes
immune microenvironment
Immunosuppressive Agents
Infiltration
Janus kinase
Liver
Liver cancer
Liver Neoplasms - drug therapy
Liver Neoplasms - metabolism
Lymphocytes
Lymphocytes T
Metastases
Mice
Microenvironments
PD-L1 protein
PD‐L1
Spleen
Stat1 protein
Transcription Factors - metabolism
Tumor cells
Tumor Microenvironment
Tumors
YAP1
Yes-associated protein
Title Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti‐PD‐1 efficacy
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fptr.7695
https://www.ncbi.nlm.nih.gov/pubmed/36576358
https://www.proquest.com/docview/2811437758
https://search.proquest.com/docview/2759000686
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYlhNJLH9tX2rSoUPYUb2zJluxj2m0IhRQTNrClB2NJE9aE2IvXLnFOueSe39hf0pEfu01LofRiHyxbtjVjfWN98w0h70EYV5tAo6eduY4vgDvKhMZRGN_6OAPi3q7oHn8RR6f-53kw71mVNhem04dY_3CzntF-r62Dp2q1vxENXVblRIrI5pd7XFo21_RkoxwVsbZyYFtF3vfC-aA767L94cS7M9Ef8PIuWm2nm8NH5Ntwox3L5HxSV2qir37TcPy_J3lMHvYolB50ZvOE3IN8RLY_FIgUmxG5f9wvuI_IOO6krZs9Ottkaq326JjGG9Hr5im5mWaLxpSFpYii6diyE1SVxTlQRJi0qi-KkmY2F6VY1cuOfPsd6IWlA_6Sa0dVQ7N8kanMsrHp14PYo3DZc3VzWhUU8oW1U4oGkf24vo2nuME2VggD7_IZOT38NPt45PQlHhzNMTRzUgYpZ1alz2BcpQMuIyYMQGQUY0b4xjUR0yGkIEIFCC9Bg06FkVGYyiDQ_DnZyoscXhLKPe3z1DWAEZIfRp7SUkkT-alEEKeV2CHvhuFOlp2SR9JpNrMERyCxI7BDdgc7SHpfXiUsxJiRSwys8BLrw_gq7dJKmkNRYxvZVl8VIXbzorOfdSdcBFb1D88et1bw196TeHZi96_-teFr8oAh5ur4l7tkqypreIMYqVJvW2_4Caa_EzE
link.rule.ids 315,783,787,1378,27936,27937,46306,46730
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VgoBLgaWFlgJGQntqtlk7cRJxKizVAt0qqrbSIiFF8QNtVDVZZRNEOHHhzm_klzDOY5eCkBCX-BA7duKZ-Bt75huA55orWypXoqZ9tC2Ha2YJ5StLoH3r4AqIpTnRnZzy8bnzdubONuBFFwvT8EOsNtyMZtT_a6PgZkP6cM0auijygccD9xpcR21nJm_D6GzNHRXQOndgnUfeGfqzjnnWpoddy6tr0R8A8yperRec4zvwoRtq42dyMSgLMZBffmNx_M93uQtbLRAlR43k3IMNnfbgxssMwWLVg5uT9sy9B_2wYbeuDsh0Hay1PCB9Eq55r6v78G2UzCuVZ8ZLFKXHZJ4gIs8uNEGQSYryMstJYsJRsmW5aPxvP2lyaTwCfwm3I6IiSTpPRGIcssn7o3BI9OfWXTclRUZ0OjeiSlAmkh9fv4cjvGAdw4WBo9yG8-PX01djq83yYEmG1pkVUx0zaoj6FJpW0mVeQLnSOlCCUsUdZauASl_HmvtCI8LUUsuYKy_wY891JduBzTRL9UMgbCgdFttKo5Hk-MFQSE94KnBiD3GcFHwXnnXzHS0aMo-ooW2mEc5AZGZgF_Y7QYhadV5G1EezkXloW-EjVrfxU5rTlTjVWYl1vDoBK_exmweNAK06Ydw1xH_Yul-LwV97j8LpmSn3_rXiU7g1nk5OopM3p-8ewW2KEKxxx9yHzSIv9WOETIV4UqvGT6fCF0k
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagoIoLj-VVKGAktKdmm3UcJzkWllV5tIqqrbSIQxTbU21UNVllE0Q4ceHOb-SXMI6TXQpCQlySQ-zYiWfib-LP3xDyAoR2lfYVetqZ63ABniN1qB2J8S3HGRDPZkX36FgcnvK3c3_esSrNXhirD7H-4WY8o_1eGwdf6rP9jWjosipHgYj8q-QaFwh8DSA62UhHRaxNHdimkefjcN4Lz7psv695eSr6A19ehqvtfDO9RT72PbU0k_NRXcmR-vKbiOP_PcptcrODofTA2s0dcgXyAbn-skCo2AzI9lG34j4gw9hqWzd7dLbZqrXao0Mab1Svm7vk2yRbNLosDEcUbcfknaCyLM6BIsSkVX1RlDQzm1GKVb207NtPQC8MH_CXzXZUNjTLF5nMDB2bfjiIxxQ-d2TdnFYFhXxhDJWiRWQ_vn6PJ3jAMkYJA3t5j5xOX89eHTpdjgdHeRibOSmD1GNGpk9jYKV8L4iY0ACRloxpwbWrI6ZCSEGEEhBfggKVCh1EYRr4vvLuk628yOEhod5YcS91NWCIxMNoLFUgAx3xNEAUp6TYIc_74U6WVsojsaLNLMERSMwI7JDd3g6SzplXCQsxaPQCjKzwFuvL-CrN2kqaQ1FjmaBNvypCbOaBtZ91I57wjewf1h62VvDX1pN4dmLOj_614DOyHU-myfs3x-8ekxsM8ZflYu6Sraqs4QnipUo-bR3jJ2R3Ffg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dihydroartemisinin+broke+the+tumor+immunosuppressive+microenvironment+by+inhibiting+YAP1+expression+to+enhance+anti%E2%80%90PD%E2%80%901+efficacy&rft.jtitle=Phytotherapy+research&rft.au=Peng%2C+Qing&rft.au=Li%2C+Shenghao&rft.au=Shi%2C+Xinli&rft.au=Guo%2C+Yinglin&rft.date=2023-05-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0951-418X&rft.eissn=1099-1573&rft.volume=37&rft.issue=5&rft.spage=1740&rft.epage=1753&rft_id=info:doi/10.1002%2Fptr.7695&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0951-418X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0951-418X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0951-418X&client=summon